The first results from the UK RIO study were presented at CROI 2025, by Professor Sarah Fidler from Imperial College London, in an oral abstract session focussed on cure-related research .
Additional results, including a potential vaccine-like cure were presented in posters by Professor John Frater and Dr Mohammed Altaf from the University of Oxford.
RIO is a randomised (1:1) placebo-controlled study looking at whether participants receiving two LS-bNABs (Arm A) could maintain viral load suppression off-ART during an analytic treatment interruption (ATI), for longer than participants who received a placebo (Arm B). Criteria to restart ART during the ATI included viral load >1000 copies/mL for six weeks or confirmed >100,000 copies/mL. The primary outcome included the time to loss of viral suppression up to week 20.
Read the full news story by Simon Collins, HIV i-Base here.
Simon Collins is a community representative on the RIO study.
SEE ALSO:
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.